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CharacterizationThe grouping of substances serves to streamline testing for regulatory purposes. General grouping
approaches for chemicals have been implemented in, e.g., the EU chemicals regulation. While speciﬁc
regulatory frameworks for the grouping of nanomaterials are unavailable, this topic is addressed in dif-
ferent publications, and preliminary guidance is provided in the context of substance-related legislation
or the occupational setting. The European Centre for Ecotoxicology and Toxicology of Chemicals Task
Force on the Grouping of Nanomaterials reviewed available concepts for the grouping of nanomaterials
for human health risk assessment. In their broad conceptual design, the evaluated approaches are consis-
tent or complement each other. All go beyond the determination of mere structure–activity relationships
and are founded on different aspects of the nanomaterial life cycle. These include the NM’s material prop-
erties and biophysical interactions, speciﬁc types of use and exposure, uptake and kinetics, and possible
early and apical biological effects. None of the evaluated grouping concepts fully take into account all of
these aspects. Subsequent work of the Task Force will aim at combining the available concepts into a
comprehensive ‘multiple perspective’ framework for the grouping of nanomaterials that will address
all of the mentioned aspects of their life cycles.
 2014 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/3.0/).r REACH
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criteria related to conceivable risks
As more and more nanotechnological products enter the mar-
ket, the importance of adequately assessing nanomaterial (NM)
exposure, biokinetics, hazard and risk is now widely recognized.
Worldwide, different governments, authorities, international orga-
nizations and other institutions are developing policy frameworks
and guidance documents relating to nanotechnology, as such, and,
speciﬁcally, to the safe development, handling and use of NMs.
Generally, the following aspects are addressed as potentially inﬂu-
encing NM hazard: The properties and biophysical interactions of
NMs, their speciﬁc types of use and exposure, uptake and kinetics,
and possible early and apical biological effects (Fig. 1; Oomen et al.,
2014a,b). However, the speciﬁc alignments and contents of guid-
ance documents for the hazard and risk assessment of NMs differ
from country to country or jurisdiction to jurisdiction.
It is expected that the safety of a substantial number of NMs
will have to be assessed. This is mainly a consequence of the very
broad deﬁnitions for ‘nanomaterial’ as they have been laid down,
e.g., by the EU Commission (2011) or the United States – Canadian
Regulatory Cooperation Council (RCC-NI, 2013a). Further taking
into account the abundance of NM modiﬁcations in regard to par-
ticle size, shape, or surface properties, the need to perform sepa-
rate or additional safety assessments of NMs as compared to
their respective bulk material counterparts could result in full-
blown testing programs for each individual NM. In terms of testing
capacities, their realization would not be accomplishable within a
reasonable timeframe. Additionally, ‘tick-box’ testing schemes are
not justiﬁable on scientiﬁc grounds since they inevitably lead to
the collection of large amounts of unnecessary data instead ofFig. 1. Source-to-adverse-outcome pathway to derive the relevant physico-chemical (blu
et al., 2014b; reprinted with the permission of the authors).focusing on relevant studies. Such testing schemes also contravene
the need to restrict animal testing in line with the 3Rs principle to
replace, reduce, and reﬁne animal testing (Russell and Burch, 1959)
that has been implemented in European legislation (EP and Council
of the EU, 2010). Concordantly, the provisions of the EU REACH reg-
ulation on the registration, evaluation, authorization and restric-
tion of chemicals prescribe that animal testing may only be
undertaken as a last resort (EP and Council of the EU, 2006).
The so-called ‘grouping of substances’ (or category approach)
has been recognized as an important means to avoid unnecessary
new testing: In this approach, closely related chemicals are consid-
ered as a group, or category, rather than as individual chemicals. . . [so
that] not every chemical needs to be tested for every endpoint. Instead,
the overall data for that category should prove adequate to support a
hazard assessment. . . [and] must enable an estimate of hazard for the
untested endpoints (OECD, 2014). For chemicals in general, techni-
cal guidance documents on grouping are available, e.g. from the
Organization for Economic Cooperation and Development (OECD)
or the European Chemicals Agency (ECHA, 2008, 2012a, 2013a,
2014; OECD, 2014). This grouping concept implies that some, if
not all, information on the hazard of a NM can be derived from
the respective bulk material, from molecules or ions of its constit-
uents, or from similar NMs.
By contrast, to date, there is little experience with the speciﬁc
grouping of NMs. Whereas molecules in solutions or vapors are
usually distinct deﬁnable species, NMs and particles generally do
not exist as distinct species. Instead, they are a population of pri-
mary particles and, preponderantly, aggregates and agglomerates
of various sizes and different surface coatings. The composition of
the NM surface and of the molecules adsorbed onto it inﬂuences
the biokinetic and toxicological properties of the respective NM,e), exposure (yellow), biokinetics (green) and hazard (red) endpoints (from: Oomen
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(Landsiedel et al., 2008, 2010, 2012a,b; Lundqvist et al., 2011;
Monopoli et al., 2011, 2012). Therefore, NM grouping should not
be restricted to the determination of nanostructure–activity rela-
tionships, but should take into account all aspects of the substance’s
entire life cycle. These aspects include the NM’s material properties
(e.g. size, shape, crystallinity) and biophysical interactions (e.g. gen-
eration of oxidative species), its intended use (and hence incorpora-
tion into the respective product and possible release therefrom), the
‘external exposure’ to the NM (i.e. the dose level and physico-
chemical form of the NM exposure outside the body), NM uptake
and ‘internal exposure’ (referring to the NM’s concentration and
physico-chemical form at the site of action in the organism), and,
ﬁnally, its biokinetics and possible early biological and apical effects
(Fig. 1). Addressing all of these aspects to group NMs allows ranking
NMs and streamlining hazard assessment to conceivable risks. Such
an approach can be put into practice in concern-based integrated
approaches for testing and assessment (IATAs).
A number of concepts for the grouping and efﬁcient testing and
assessment of NMs have been published or are under discussion in
on-going national or international political incentives or scientiﬁc
research projects. These concepts base NM grouping on their struc-
ture and material properties (and material functions), their expo-
sure, uptake and kinetics, and initiating cellular or apical effects.
In the present survey, the ECETOC (European Centre for Ecotoxico-
logy and Toxicology of Chemicals) Task Force (TF) on grouping and
IATAs of nanomaterials reviewed and evaluated available concepts
for the grouping of NMs as far as they concern human health haz-
ard and risk assessment. Environmental hazard assessment was
excluded from the scope of the survey as was the hazard assess-
ment of NMs developed for medical, pharmacological and pharma-
ceutical purposes.
As a starting point for the overview on NM grouping concepts,
Section 2 presents and discusses deﬁnitions for the term ‘nanoma-
terial’ and related terms, and Section 3 summarizes existing poli-
cies or regulatory frameworks for nanotechnology related to the
hazard, exposure, risk assessment and handling of NMs. Informa-
tion is provided for the European Union as the operative area of
ECETOC, and exemplarily as important economies with detailed
provisions on NMs, the USA, Canada, Japan, and Australia. Section
4 outlines existing regulatory concepts for the grouping of chemi-
cals, as such. Section 5 presents and discusses recent conceptual
proposals and research projects addressing the grouping of NMs,
and Section 6 provides referenced examples on how such incen-
tives are being put into practice in NM hazard assessment studies.
Finally, a conclusion is provided in Section 7.2. Deﬁnitions related to nanomaterials
To date, there is no uniformly accepted deﬁnition of what in fact
constitutes a ‘nanomaterial’. In 2008 and 2010, the International
Standardization Organization (ISO) has provided overarching tech-
nical deﬁnitions for nanotechnology-related terms: ‘Nanomaterial’
is deﬁned asmaterial with any external dimension in the nanoscale or
having internal or surface structure in the nanoscale,with ‘nanoscale’
deﬁned as the size range from approximately 1 nm to 100 nm (ISO/TS
27687, 2008; ISO/TS 80004-1, 2010). However, as discussed in fur-
ther detail in Section 1 of the Supplementary Information (SI) and
summarized in Table SI-1, different jurisdictions, committees, or
societies have set up different deﬁnitions for the term ‘nanomate-
rial’, which further differ in regard to their determination of the
‘nanoscale’ (cf. Table SI-2).
All deﬁnitions of a ‘nanomaterial’ include the size range from
approximately 1–100 nm, and none of the deﬁnitions take into
account actual concerns in respect to the materials’ adverse effectson human health or the environment. The EU deﬁnition (EU
Commission, 2011) is the only deﬁnition that includes natural or
accidentally occurring nanoparticles, whereas all other deﬁnitions
are restricted to ‘intentionally produced, manufactured, or engi-
neered NMs’. Furthermore, the different deﬁnitions are not consis-
tent in regard to their mentioning of the state of aggregation or
agglomeration of the nanoparticles, which in many cases however
is the predominant state in relevant exposure scenarios: While
some deﬁnitions do not mention this issue at all, others include
aggregates and/or agglomerates, and one deﬁnition even explicitly
excludes aggregates and agglomerates e.g. if the corresponding NM
cannot be readily broken down into nano-objects. Two deﬁnitions
speciﬁcally indicate insolubility and/or biopersistence – two fur-
ther important aspects of nanoparticle characteristics, and only a
few deﬁnitions take particle size distribution into account in their
deﬁnition. Notably, since the EU deﬁnition is based on the size dis-
tribution of the constituent particles of a material expressed in num-
ber metrics (EU Commission, 2011; cf SI), nearly every powder can
be considered a nanomaterial as long as further guidance is
unavailable on the term ‘constituent particle’ and on the dispersion
method to prepare samples for measurement.
In summary, in spite of many years of intensive endeavors to
agree upon an adequate deﬁnition for the term ‘nanomaterial’,
far-reaching consensus on this term has not been achieved and is
not foreseeable on the short- or mid-term. The EU has already
announced the revision of its deﬁnition that was established in
2011: By December 2014, the deﬁnition [. . .] will be reviewed in the
light of experience and of scientiﬁc and technological developments.
The review should particularly focus on whether the number size dis-
tribution threshold of 50% should be increased or decreased (EU
Commission, 2011).
The lack of decisive deﬁnition for the term ‘nanomaterial’ and
the discussions about appropriate aspects and thresholds to be
included allow the conjecture that scientiﬁcally justiﬁable param-
eters or thresholds for ‘nanomaterials’ which are generally relevant
for safety assessment do not exist. All available deﬁnitions are
based on material properties. While they are conceived and
applied to found regulatory provisions for safety assessment, the
deﬁnitions are not derived from toxicological evidence of a step-
change in toxicity at 100 nm or any other single overarching mate-
rial property applicable to all ‘nanomaterials’. Speciﬁc concerns
that have been recognized for speciﬁc types of NMs do not relate
to their nanosize, but, e.g., to their respective chemical composi-
tion or shape. There is no evidence of a novel ‘nano-speciﬁc haz-
ard’. Instead, there is likely to be a more gradual magniﬁcation of
the intrinsic hazard of increasingly small particles, e.g. in relation
to surface area (Donaldson and Poland, 2013).
Since nanosize per se does not drive a speciﬁc toxicity
(Donaldson and Poland, 2013), application of a general technol-
ogy-based material deﬁnition to establish hazard information
requirements of a broad spectrum of materials with different tox-
icologically relevant properties is likely to be incomplete or even
ﬂawed. It may result in performing the wrong tests or omitting rel-
evant tests thereby leading to overestimation of certain hazards,
while others remain undetected. Therefore, from the point of view
of the ECETOC TF, all deliberations on NMs should take into
account multiple perspectives, just as the grouping of NMs should
address all aspects of the life cycle of the respective material
within the context of its intended use.
3. Regulatory frameworks for nanotechnology and
nanomaterials
Concepts for the grouping of NMs have to comply with regula-
tory frameworks and legal provisions that have been implemented
for nanotechnology and NMs. Otherwise, they cannot be applied to
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in the given regulatory context. Therefore, this section provides an
overview of regulatory frameworks for nanotechnology and NMs
that have been implemented in different jurisdictions, speciﬁcally
the European Union as the predominant business area of ECETOC
and its members (Table SI-3), and additionally, as important econ-
omies from different geographical regions, USA (Table SI-4), Can-
ada (Table SI-5), Japan (Table SI-6), and Australia (Table SI-7). As
all tables reveal, most jurisdictions have published policy frame-
works outlining their commitment to nanotechnology while at
the same time conﬁrming their dedication to ensuring a high level
of safety of nanotechnological developments for workers, consum-
ers, and the environment. As a rule, concrete provisions prescribing
speciﬁc information requirements for the hazard and risk assess-
ment of NMs have not been adopted in legal acts. Instead, NMs
are considered to be generally covered by existing substance-
and product-related legislation, and responsible authorities have
issued initial guidance on the hazard and risk assessment of NMs
or on appropriate risk management measures in the occupational
contexts (cf. Section 2 of the SI and Tables SI-2–SI-7 for further
details on the different regulatory frameworks and guidance
published in the EU, USA, Canada, Japan, and Australia). As a rule,
precise, detailed guidance on NM safety assessment is still under
discussion. Therefore, all current initiatives addressing the differ-
ent aspects of a science-based NM risk assessment can be consid-
ered in on-going regulatory activities.
4. Concepts for the general grouping of chemicals
In all jurisdictions, regulatory guidance documents are available
addressing the categorization and grouping of chemicals as such,
i.e. guidance from the European Union (ECHA, 2008), the US EPA
in context of its High Production Volume (HPV) Challenge Pro-
gram,1 the Canada Substance Grouping Initiative, and the Japan
HPV Challenge Program.2 Likewise, the OECD has published guid-
ance for the grouping of chemicals. First released in 2007 borne
out of previous work from ECHA (OECD, 2007), on 14 April 2014, a
second edition has been published (OECD, 2014; cf. Section 3 of
the SI for further information on the OECD work related to NMs).
The OECD/ECHA analogue and category approaches are
described as techniques for grouping chemicals. The analogue
approach implies that grouping is based on a limited number of
chemicals. Endpoint information for one chemical is used to pre-
dict the same endpoint for another chemical, which is considered
to be ‘similar’, even though trends in properties (a term used in
the OECD guidance to describe regular patterns of properties as a
result of structural (or other) similarities) are not necessarily
apparent. The category approach implies that chemicals can be
grouped by physico-chemical, human health and/or ecotoxicologi-
cal and environmental fate properties that are likely to be similar
or follow certain trends. More members are generally present in
a chemical category than upon application of the analogue
approach, enabling the detection of trends across endpoints. The
data for chemicals and endpoints that have been tested are used
to estimate the corresponding properties for the untested chemi-
cals and endpoints. Therefore not every chemical needs to be
tested for every required endpoint. The overall category data and
rationale should be adequate to support a screening-level hazard
assessment (OECD, 2014; ECHA, 2008).
Different techniques are mentioned that can be applied to ﬁll
data gaps in a chemical category: For trend analysis, models are
used that are based on the data for the members of the category.
Likewise, (quantitative) structure activity relationships ((Q)SARs)1 http://www.epa.gov/hpv/pubs/general/catgrfnl.pdf.
2 http://www.env.go.jp/en/chemi/hpv.html.can be applied, and in external QSAR models the category under
examination is a subcategory of a wider QSAR (To increase the reg-
ulatory acceptance of (Q)SAR methods, the OECD has promoted the
development of a QSAR Toolbox3). Read-across is a technique used
to predict endpoint information for one chemical by using data from
the same endpoint from another chemical which is considered to be
‘similar’ in some way. In general, ‘interpolation’ (i.e. the process
whereby data from category members on either side of a data-poor cat-
egory member is used to predict its hazard (OECD, 2014)) is preferred
to ‘extrapolation’ between category members (i.e. the process where
data from category members at one side of the category is used to pre-
dict the hazards of those members at the other side (OECD, 2014)).
The OECD guidance highlights that application of the chemical
category approach can be more efﬁcient and accurate than a
one-by-one assessment of single compounds: The identiﬁcation of
compounds as members of a category provides an insight into the
potential effects of the compounds that might otherwise be overlooked.
Thereby, also the evaluation of compounds that are often considered
as ‘difﬁcult’, in the sense that they can present technical difﬁculties
when carrying out standard test protocols, may be improved
(OECD, 2014).
Although chemical grouping and read-across are being widely
practiced, the potential for these approaches to introduce addi-
tional uncertainty into hazard and risk assessment is broadly
acknowledged (ECHA, 2008; ECETOC, 2012; OECD, 2014). The
OECD guidance discusses a number of practical and scientiﬁc hur-
dles to consider when grouping chemicals, such as gaining access to
good quality data that are required for the data gap ﬁlling approach or
the level of mechanistic understanding required for speciﬁc endpoints
to help inform the biological plausibility of grouping.
In principle, all grouping concepts have to surpass the same
scientiﬁc hurdles regardless of the type or size of the substances
under evaluation. As summarized by ECETOC (2012) and
Patlewicz et al. (2013), also for non-nanosized chemicals, compar-
isons of the spectrum of relevant physico-chemical properties of
the analogue and target substances as well as their likely toxicoki-
netics and molecular initiating events are addressed as key param-
eters to perform and justify grouping. Likewise, all substances,
regardless of their size, have to be assessed throughout their
expected life cycle.
Overall, authorities and industry are still at a learning phase on
how to apply grouping concepts for chemicals most appropriately
(ECHA, 2012a,b; ECETOC, 2012). Patlewicz et al. (2013) highlight
that difﬁculties remain in applying category approaches and
read-across consistently in practice. They address scientiﬁc
challenges in preparing scientiﬁcally valid and robust read-across
justiﬁcations that build on the knowledge of the presumed
mode-of-action (MoA) driving the endpoint(s) under consider-
ation. Patlewicz et al. underline the importance of a clear rationale
underpinning the respective analogue or category approach, and to
evaluate analogues by general and endpoint-speciﬁc aspects. Data
on toxicokinetics are addressed as a key piece of evidence to
support justiﬁcations. Integrating knowledge on how chemicals
interact with biological systems (i.e. their molecular initiating
events) with knowledge on the responses they can elicit at increas-
ing levels of biological complexity are addressed as a means to
derive chemical categories that allow predicting longer-term
effects. Notwithstanding, full knowledge on the pathway from ini-
tial molecular initiating event to the ﬁnal adverse outcome is not
considered necessary to build a chemical category (Wu et al.,
2010; ECETOC, 2012; Patlewicz et al., 2013).
To introduce more transparency to the degree of read-across
uncertainty, Blackburn and Stuard (2014) have proposed a3 http://www.oecd.org/chemicalsafety/risk-assessment/theoecdqsartoolbox.htm.
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account the robustness of analogue data sets, the concordance of
effects or potencies, and the severity of critical effects. By assigning
available data to these categories, the level of uncertainty of an
analogue-based read-across assessment can be assigned transpar-
ently, allowing standardization of read-across measures and facil-
itating consistency in read-across conclusions drawn by different
risk assessors (Blackburn and Stuard, 2014).
5. Concepts for the speciﬁc grouping of nanomaterials
5.1. Activities promoting the grouping of NMs in the context of
substance-related legislation
Speciﬁc regulatory guidance on the grouping of NMs has not yet
been published in the European Union (or elsewhere). Also the sec-
ond edition of the OECD guidance speciﬁcally excludes recommen-
dations on the grouping of NMs: At present, it seems premature to
develop guidance on grouping speciﬁcally for NMs. Nevertheless,
research efforts will pave the way for common approaches and frame-
works to grouping NMs for purpose of hazard assessment in the future
(OECD, 2014).
However, different authorities have released documents refer-
ring to NM grouping (Table 1). As a rule, they outline general
requirements for grouping and emphasize, e.g. the need for sound
scientiﬁc justiﬁcations to support the application of read-across
techniques. In the 2nd best practices report from the Group
Assessing Already Registered Nanomaterials (GAARN), ECHA (2013b)
conﬁrms the usefulness of grouping measures in fulﬁlling the
information requirements for NMs under REACH provided that
they are accompanied by a solid scientiﬁc justiﬁcation: It isTable 1
Activities promoting the grouping of NMs in the context of substance-related legislation.
Publication/activity Key element of approach Physico-chemical
characterization
Exp
ECHA (2013b). Best prac-
tices report of the
ECHA Group Assessing
Already Registered
Nanomaterials
(GAARN)
Importance of ‘solid
scientiﬁc justiﬁcation’ for
grouping
Chemical composition
alone is insufﬁcient,
additionally, e.g.,
aspect ratio, shape,
form, solubility,
surface area, charge,
surface treatment
German Competent
Authorities (2011).
Position paper on
nanomaterials and
REACH
Waiving of testing for
NMs by referencing
between bulk and
nanoform, different
nanoforms, read-across
between different
substances
Araki et al. (2013). ICCR
Working Group on
safety approaches for
NMs in cosmetics
‘Bridging toxicity
approach’ to extrapolate
toxicity data between
selected non-nano and
nanoforms, or between
different nanoforms of
the same NM
Anzai et al. (2012). Nan-
oDiversity Evaluation
SchemeTM
Classiﬁcation by
directness of human
exposure and production
volume
NM
use
of
US Canada RCC-NI, 2013.
Report on the
development of a
classiﬁcation scheme
for NMs regulated
under the US and
Canada New
Substances Programs
Recognize‘ NMs of
concern’ that are likely to
behave differently from
their bulk or molecular
counterparts and
therefore require speciﬁc
risk assessment
7 classes of NMs: CNTs,
inorganic carbon,
metal oxides, metals,
quantum dots,
organics and ‘other’.
Cla
sim
com
pre
pro
on
frainsufﬁcient to base the justiﬁcation only on the NM’s chemical compo-
sition, but further physico-chemical parameters such as aspect ratio,
shape, form, solubility, surface area, charge, surface treatment, etc.
should be provided to support a sound scientiﬁc interpretation of the
similarities or differences among (nano)forms.
This best practices report (ECHA, 2013b) is based upon the eval-
uation of 3 registration dossiers including nanoforms and NMs, but
without making speciﬁc reference to these dossiers or providing
any other examples. It further recommends applying the general
similarity rules (or ‘criteria’) speciﬁed in Annex XI of the REACH
regulation also for the grouping of NMs, basing similarities on:
(a) Common functional groups;
(b) Common pre-cursors and/or the likelihood of common break-
down products via physical and biological processes, which
result in structurally similar chemicals; or
(c) A constant pattern in the changing of the potency of the prop-
erties across the category.
The basis for the grouping should be used to deﬁne what
characteristics a NM should have in order to belong to a category.
The similarity rules might be used individually and are case-
dependent. Nevertheless, a category or similarity may be justiﬁed
on more than one basis, which will usually increase conﬁdence
in the category. The basis for the grouping will help show for which
endpoints the grouping applies, and if it is adequate for all routes
of exposure and durations of effects (ECHA, 2013b).
Furthermore, the 3rd best practices report from the GAARN
(ECHA, 2014) generally emphasizes that registration dossiers
should contain a comprehensive physico-chemical characterization
of the registered nanoform(s) and underlines the importance ofosure Biokinetics Hazard
The likelihood of
common breakdown
products resulting in
structurally similar
chemicals;
consideration of
toxicokinetics for
grouping
Constant pattern in the
changing of the potency of
the properties across the
category
On the basis of similar
toxicity proﬁles in short-
term toxicity studies,
combined with
genotoxicity and
toxicokinetics, toxicity data
extrapolation may be
justiﬁed
uptake during intended
; special consideration
chemical substances
ssiﬁcation of NMs by
ilarities in chemical
position is considered
ferable for regulatory
grams, which are based
traditional chemical
meworks
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ing: Generating data on toxicokinetics might also be considered for
grouping substances in relation to read-across approaches, or extrap-
olating from in vitro to in vivo situations (ECHA, 2014).
In line with this recommendation, in November 2013, CARACAL,
the meeting of the EU Competent Authorities for REACH and CLP, sta-
ted that with the current understanding of REACH, it is possible
and even encouraged that different forms of the otherwise same
substance are registered in a single dossier as long as it is scientif-
ically meaningful to share data. Accordingly, a scientiﬁc justiﬁca-
tion is required for the application of read-across techniques
between the different forms of a substance.
In a position paper on nanomaterials and REACH, the German
competent authorities in charge of hazard assessment describe
three conceivable scenarios for waiving of testing during NM haz-
ard assessment, i.e. (1) use of data by referencing between the bulk
and nanoform of a substance; (2) use of data by referencing
between different nanoforms of a substance, (3) read-across
between substances with different chemical identities (possibly
various bulk and nanoforms) (German Competent Authorities,
2011). Approaches for grouping and waiving are recognized to be
particularly important for substances having a large number of dif-
ferent nanoforms. The German position further anticipates that
waiving will be rare in the beginning, but has the potential to
increase to the extent that standardized tests show that results
from substances in bulk form can be utilized for NM hazard assess-
ment (German Competent Authorities, 2011).
In the light of the European Union marketing ban for cosmetic
ingredients and products, the International Cooperation on
Cosmetics Regulation (ICCR; a voluntary partnership among the
health authorities of Canada, Europe, Japan, and the USA, with
participation and technical support from the cosmetics industry
associations of the four jurisdictions) Working Group on safety
approaches for NMs in cosmetics has suggested a ‘bridging toxicity
approach’ to extrapolate toxicity data between selected non-nano
and nanoforms, or between different nanoforms of the same NM.
Due to prevailing knowledge gaps, the use of read-across or catego-
rization approaches based on inter- or intra-NM extrapolation are
not considered feasible for safety assessment. However, on the basis
of similar toxicity proﬁles in short-term toxicity studies, together
with the outcome of genotoxicity and toxicokinetics, the extrapola-
tion of toxicity datamaynevertheless be justiﬁed (Araki et al., 2013).
Also with a special focus on cosmetics, the NanoDiversity
Evaluation Scheme™ published by Anzai et al. (2012) foresees
classifying NMs (and determining information requirements) by
the directness of human exposure and production volume. Accord-
ingly, the NanoDiv™ grouping concept focuses on NM uptake and
internal exposure: In the ﬁrst step, NMs are categorized as to
whether they are expected to enter the human body (due to their
intended use), or not. The NM’s production volume is addressed as
further fundamental parameter: If the annual production or import
volume of the NM is less than 10 tons, or the NM content of the
product is below this amount, low volume exemption, as it has
been laid down in, e.g., the REACH regulation, is applied to the
product. (However, the authors acknowledge that this threshold
value might not be appropriate for NMs.) If the annual production
or the sales volume exceeds 10 tons, the NanoDiv™ scheme distin-
guishes whether the NM is used as a raw material or as a con-
sumer-used product. In both cases, different sets of tests are
required depending on whether the NM will be used as cosmetic
ingredient, or not.
If the NM is not for cosmetic use, and end-users will not apply
the NM directly to their skin, the NanoDiv™ scheme addresses the
respiratory system as the main target organ. Anzai et al. (2012)
foresee testing to be performed in tiers, beginning with in vitro
screening assays and moving on to acute and subchronic in vivostudies. Long-term testing is only required if the initial tiers pro-
vide an indication for, e.g., carcinogenicity or reproductive and
developmental toxicity (Anzai et al., 2012).
If the NM is intended for cosmetic use, the NanoDiv™ scheme
requires assessing eye and skin toxicity in addition to respiratory
tract toxicity. Additionally, dermal penetration and genotoxicity
are assessed in early-tier studies. If their results indicate that addi-
tional long-term testing is necessary, either transdermal or carcin-
ogenicity testing, or both, are performed. Based on the results of
the early tiers, reproductive and developmental toxicity tests by
inhalation are also carried out if necessary (Anzai et al., 2012). Of
note, however, Anzai et al. do not address that, in accordance with
the EU cosmetic products regulation (EP and Council of the EU,
2009), animal studies may not be performed for the human hazard
assessment of cosmetic ingredients or products. Furthermore, to
date relevant transdermal penetration of NMs that are intended
for use in, e.g., sunscreen lotions has neither been observed in
intact or sunburned skin, either in vitro or in vivo (Monteiro-
Riviere et al., 2011).
In respect to the new substances programs of Canada and the
United States, RCC-NI (2013a) published a draft report on the devel-
opment of a classiﬁcation scheme for NMs regulated under these
programs. The classiﬁcation scheme aims at recognizing ‘NMs of
concern’ that are deﬁned as NMs, which are likely to behave differ-
ently on the nanometer scale than their bulk or molecular counter-
parts and therefore require speciﬁc risk assessment: The purpose of
the classiﬁcation scheme is to develop a framework to (1) identify
which classes of NMs typically require nanospeciﬁc considerations in
risk assessment; and (2) support the selection of appropriate analogue
and/or read-across information for substance-speciﬁc risk assessments
for NMs. In addition, the scheme aims at highlighting the type of infor-
mation needed for characterization of the NMs within each class. . .
The classiﬁcation system is intended to be continually reﬁned. . . as
more scientiﬁc knowledge becomes available (RCC-NI, 2013a).
For the time being, RCC-NI (2013a) addresses classiﬁcation of
NMs by similarities in chemical composition as preferable for
regulatory programs, which are based on traditional chemical
frameworks. By contrast, grouping according to toxicological infor-
mation is not yet considered possible. Accordingly, the RCC-NI pro-
poses a chemical classiﬁcation scheme for NMs distinguishing
between 7 classes of NMs, i.e. CNTs, inorganic carbon, metal oxides,
metals, quantum dots, organics and ‘other’. For each class, speciﬁc
physico-chemical parameters are listed that are relevant for the
respective sub-classiﬁcations (RCC-NI, 2013a). Furthermore, the
RCC-NI (2013b) developed a scheme for focusing concerns and
additional testing requirements for novel nanoparticles (Fig. 2).
5.2. Concepts for the grouping of nanomaterials for occupational safety
assessment
Speciﬁc legal provisions setting information requirements for
nanomaterial hazard assessment are largely unavailable. Scientists
from different national health authorities and committees have
published frameworks for nanomaterial safety assessment. A num-
ber of these frameworks include algorithms to broadly group NMs
by common denominators (Table 2). As suggested in the respective
publications, these algorithms can be applied to prioritize NMs for
testing and for assessing e.g. occupational or consumer-related
hazards.
The classiﬁcation scheme of the British Standards Institute cate-
gorizes NM types into four groups that combine physico-chemical
properties of the NMs and toxic effects reported for their
non-nanosized counterparts, i.e. (i) ﬁbrous NMs; (ii) NMs whose
non-nanosized counterparts are already classiﬁed as carcinogenic,
mutagenic, asthmagenic or reproductive toxins (CMAR); (iii)
insoluble or poorly soluble NMs that are neither classiﬁed as
Fig. 2. Schematic for focusing concerns for novel nanoparticles (from: RCC-NI, 2013b; reprinted with the permission of the authors).
Table 2
Concepts for the grouping of nanomaterials for occupational safety assessment.
Activity Key element of approach Deﬁnition of 4 different classes of nanomaterials, based upon
Solubility Biopersistence; low toxicity Biopersistence; higher toxicity High aspect ratio
British
Standards
Institute; cf.
https://
nanohub.org/
groups/gng/
guidelines
Combine physico-chemical properties
of the NMs and toxic effects reported
for their non-nanosized counterpart;
relate OELs to the OELs of the bulk
counterparts
Soluble NMs that
are not assigned
to any other
category
Insoluble or poorly soluble
NMs that are neither
classiﬁed as ﬁbrous, nor
CMAR
NMs whose non-nanosized
counterparts are already
classiﬁed as carcinogenic,
mutagenic, asthmagenic or
reproductive toxins (CMAR)
Fibrous NMs
BAuA (2013)
German Fed-
eral Institute
for Occupa-
tional Safety
and Health
NM hazard assessment should at least
be based on effects induced due to
speciﬁc chemical composition and on
effects caused by biopersistence
Soluble NMs Biopersistent NMs without
inherent toxicity (granular
biopersistent particles that
possibly inducing pulmonary
inﬂammation)
Biopersistent NMs with
speciﬁc toxicity (i.e. release of
toxic ions, activity of chemical
functional groups, catalytic
activity)
Biopersistent, ﬁbrous
NMs
Kuempel et al.
(2012) from
US NIOSH)
Categorization based upon
toxicological MoAs; suggest
‘benchmark’ reference substances for
each MoA class for which full data set
will be available and to compare
limited data sets of further NMs
against benchmark chemicals
Higher solubility
particles
shedding toxic
ions that can
reach systemic
tissues
Poorly soluble, low-toxicity
particles, where surface area
dose of the inhalable
particles determines toxicity
Poorly soluble, high-toxicity
particles where reactive
particle surface area dose
determines toxicity
Fibrous particles
(toxicity related to
biopersistence, particle
migration to the lung
pleura, genotoxicity)
DHHS (NIOSH)
(2012) con-
trol banding
scheme
Develop control banding scheme to
select from among a limited set of
available exposure control techniques
those that will most effectively protect
the health of workers
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any other category (cf. BSI Published Document (PD) 6699-2, Nano-
technologies – Part 2: Guide to safe handling and disposal of man-
ufactured NMs4). The BSI standard is one of the ﬁrst documents to
suggest OELs for the respective groups of NMs, i.e. 0.01 ﬁbers/mL
for ﬁbrous NMs; 0.1 of the existing OEL for CMAR NMs; 0.066 of
the existing OEL for insoluble NMs; and 0.5 of the existing OEL for
the soluble NMs.
The German Federal Institute for Occupational Safety and Health
has published an Announcement regarding hazardous substances for
NMs that speciﬁcally addresses inhalation as the predominant
route of exposure (BAuA, 2013). This announcement requires at
least basing hazard assessment on effects induced due to the spe-
ciﬁc chemical composition of the NMs and on effects caused by
biopersistence of the object (measured by the degree of water sol-
ubility). Taking into account toxicological properties, material
properties (shape and structure) and biopersistence, the announce-
ment foresees four groups of substances, i.e. soluble NMs, biopersis-
tent NMs with speciﬁc toxicological properties (i.e. release of toxic
ions, activity of chemical functional groups, and catalytic activity),
biopersistent NMs without toxicological properties (granular bio-
persistent particles that may possibly induce pulmonary inﬂamma-
tion), and biopersistent, ﬁbrous NMs (BAuA, 2013; Packroff, 2013).
Hartwig (2013), chairing the Commission for the investigation of
health hazards of chemical compounds in the work area of the German
Research Foundation suggests the same scheme to group NMs by
speciﬁc chemical properties and additionally takes into account
whether NMs are intended for medicinal use. As regards grouping
NMs by area of use, the German Federal Environmental Agency
published a report whose actual goal was to assess impacts of an
European register of products containing NMs (UBA, 2014). In this
report, a classiﬁcation framework is presented to group products
containing NMs into the following sectors or categories: sub-
stances, cosmetics, health care, food & feed, coatings & inks, clean-
ing & disinfection, rubber products, building & construction,
textiles, paper products, and complex objects & other products.
Consistent with the NM categorization scheme proposed by
BAuA (2013), Kuempel et al. (2012) from the US NIOSH propose
four MoA classes for a broad categorization of NMs, i.e. (i) higher
solubility particles shedding toxic ions that can reach systemic tis-
sues; (ii) poorly soluble, low-toxicity particles, where surface area
dose of the inhalable particles determines toxicity; (iii) poorly sol-
uble, high-toxicity particles where reactive particle surface area
dose determines toxicity; (iv) ﬁbrous particles for which toxicity
is presumably related to biopersistence, particle migration to the
lung pleura, and genotoxicity.
Kuempel et al. (2012) suggest selecting ‘benchmark’ materials
for each of the above-mentioned MoA categories. For such bench-
mark materials, sufﬁcient dose–response data for quantitative risk
assessment should be available. New NMs are classiﬁed in accor-
dance to the hazard and risk estimates of the corresponding bench-
mark substances exhibiting the same MoA. A key challenge in
setting MoA-based classes and sub-classes recognized by Kuempel
et al. is obtaining adequate dose–response data to systematically
evaluate the physico-chemical factors inﬂuencing the biological
activities of NMs.
In the absence of occupational exposure limits (OELs) for most
NMs, the US NIOSH has published guidance on developing an occu-
pational control scheme, i.e. the so-called control banding (DHHS
(NIOSH), 2012). The ultimate goal of control banding is to select
from among a limited set of available exposure control techniques
those that will most effectively protect the health of workers4 https://nanohub.org/groups/gng/guidelines and: http://ohsonline.com/articles/
2008/02/bsi-british-standards-takes-lead-in-nano-guidance.aspx.(Gordon et al., 2014). Such techniques, ranked by their purpose to
manage minor to severe hazards, cover (i) application of good
industrial hygiene practices and general ventilation; (ii) application
of engineering controls (e.g. local exhaust ventilation); (iii) process
enclosure; and (iv) seeking expert advice (DHHS (NIOSH), 2012).
Developing OELs for representative benchmark particles within
each of the above-mentionedMoA categories would provide a basis
for linking the health effects data of NMs with limited data to the
appropriate exposure control bands (Kuempel et al., 2012).
Similarly, the research organization TNO – Innovation for Life,
located in the Netherlands, published the risk-banding tool ‘Stof-
fenmanager Nano vs. 1.0’ to prioritize NM health risks by combin-
ing available NM hazard information with a qualitative estimate of
potential worker inhalation exposure (van Duuren-Stuurman et al.,
2012). Already in 2008, the Swiss Federal Ofﬁce for Public Health
released a precautionary matrix for synthetic NMs serving to iden-
tify potentially hazardous NMs. This matrix is based on the
assumption that – throughout the NM’s life cycle – risks can only
arise if particles being on the nanoscale in two or three dimensions
(i.e. nanorods or nanoparticles) can be released (Höck et al., 2008).
Also the Quebecois Research Institute for Health and Occupational
Safety published a control banding tool for NMs similar to the
one from the US NIOSH that groups NMs by hazard and emission
potential to help deﬁne action plans in the occupational setting
(Ostiguy et al., 2010; Riediker et al., 2012).
5.3. Concepts for the grouping of NMs presented in different research
projects
A plenitude of research projects funded with public or private
resources focus on NM hazard assessment, and a number of these
projects also address the grouping of NMs. The grouping consider-
ations published in the context of the following EU-funded projects
(as well as of the Nanotechnology Industries Association) comple-
ment each other and therefore are presented and discussed jointly
in this section (cf. Table 3):
 The project MARINA (www.marina-fp7.eu), funded under the
European Commission’s 7th Research Framework Programme
(FP7), has the scope to develop and validate risk assessment
and risk management methods for NMs (van Tongeren et al.,
2013).
 The NanoSafety Cluster (www.nanosafetycluster.eu) is a Euro-
pean Commission initiative to maximize the synergies between
existing FP6 and FP7 projects addressing all aspects of nanosaf-
ety (Savolainen et al., 2013; Oomen et al., 2014a, 2014b).
 The FP7 project ITS-NANO (www.its-nano.eu) aimed at devel-
oping a research strategy concerning the interactions of NMs
with biological systems in order to intelligently design nanosaf-
ety evaluation and risk assessment strategies, identify high risk
materials, and implement effective strategies to counter the
risks (Stone et al., 2013, 2014).
 The overarching objective of the FP7-funded NanoMILE project
(http://nanomile.eu-vri.eu) is to formulate a paradigm for the
mode(s) of interaction between NMs and organisms or the envi-
ronment (Lynch et al., 2014).
 The FP7-fundedNanoSolutions project (nanosolutionsfp7.com)
whose overarching aim is to provide a means to develop a safety
classiﬁcation for engineered NMs based on an understanding of
their interactions with living organisms at molecular, cellular
and organism levels.
As discussed in further detail by Oomen et al. (2014a,b), more
than a dozen material properties and biophysical interactions of
NMs have been identiﬁed that could potentially contribute to
hazardous effects. Some of these characteristics also inﬂuence
Table 3
Concepts for the grouping of nanomaterials presented in different research projects or put into practice in the context of research activities.
Project/publication Overall grouping concept Key element of approach Addressed aspects of
nanomaterial properties
throughout its life cycle
Ph.-
ch.
Exp. Biokin. Haz.
MARINA (van Tongeren
et al., 2013); NanoSaf-
ety Cluster (Oomen
et al., 2014a,b)
NMs can be grouped by:
 Their production, use and release (throughout the life
cycle)
 The physico-chemical characteristics of a NM, which
can be different in different life cycle stages (e.g.
release and external exposure of organisms)
 The physico-chemical characteristics of a NM, which
can be different in different life cycle stages (e.g.
release and external exposure of organisms)
 The uptake, biodistribution, and biopersistence
(biokinetics) of a NM in an organism and the physico-
chemical characteristics of a NM inside the organism at
different target sites
 The early and apical biological effects
Grouping should take into account all aspects of the
NM during its life cycle. The grouping concept is closely
linked to IATAs, since both serve to recognize and
reﬁne concerns
x x x x
National Industries
Association NIA (2013)
Suggest a broad spectrum of criteria that might be used
for the grouping of NMs, i.e. high aspect ratio NMs,
rigidity, metal oxides, ion generation, ROS generation
(reactive oxygen species), crystalline structure,
organic/inorganic, softness/hardness, lipid/non-lipid,
quantum effects, natural complex substances,
inhalation studies
x x
ITS-Nano (Stone et al.,
2013, 2014)
The MoAs of NMs and how they relate to a deﬁned set
of physico-chemical characteristics is seen as crucial in
developing grouping, ranking, or modeling tools
Physico-chemical, exposure, and hazard identiﬁcation
are key elements of NM risk assessment; these
identities should be applied to group NMs
x x x
NanoMILE (Lynch et al.,
2014)
Intrinsic (inherent) properties (e.g. shape, porosity,
structural conﬁguration and band gap); chemical
composition (inherent molecular toxicity, charge,
hydrophobicity and coating); and extrinsic properties
(alterations in binding of biomolecules – interaction
with media, formation of molecular coronas - and
resultant biomolecule conformational effects (e.g.
unfolding, receptor activation, membrane damage,
ﬁbrillation etc.)
Grouping strategy that interlinks key physico-chemical
descriptors to predict nanoparticle toxicity as the sum
of three quantiﬁable parameters capturing the
diversity of MoAs
x
Nano-solutions (2013) Provide a means to develop a safety classiﬁcation for
engineered NMs based on an understanding of their
interactions with living organisms at molecular,
cellular and organism levels
Development of a computer program evaluating the
properties of engineered NMs to predict their ability to
cause health or environmental hazards
X X X
UC CEIN USA e.g. Nel et al.
(2013)
Predictive toxicological approach using mechanism-
based in vitro assays for high-throughput screening
(HTS) of NMs
Address major mechanisms of NM toxicity x
Lai (2012). US EPA High-throughput screening NM toxicity testing
paradigm
Select reference materials for different classes of NMs
having unique physico-chemical characteristics, which
may lead to different biological effects by different
MoA
x x
Shaw et al. (2008). Har-
vard Univ, USA
Perturbational proﬁling of NM biological activity x x
Cho et al. (2013). Univ.
Edinburgh, UK
Mechanism-based predictive testing approach x x
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reaches the target site in the organism, whereas potentially other
– or another set of – material properties and biophysical interac-
tions inﬂuence their biological effects. This can confound the corre-
lation between one single material property and an apical effect.
Oomen et al. conclude that due to the complexity of NMs, NM
grouping should not be restricted to determination of simple nano-
structure–activity relationships, but take into account all aspects of
their life cycles.
Accordingly, NMs can be grouped by:
 Their production, use and release (throughout the life cycle);
 The physico-chemical characteristics of a NM, which can be dif-
ferent in different life cycle stages (e.g. release and external
exposure of organisms);
 The uptake, biodistribution, and biopersistence (biokinetics) of
a NM in an organism and the physico-chemical characteristics
of a NM inside the organism at different target sites; The early and apical biological effects (Fig. 1).
In such a ‘multiple perspective’ categorization framework, a
given NM is likely to belong to more than one group. To enable
applying the grouping approach for regulatory purposes, grouping
criteria need to be established that allow justifying the use of read-
across measures to ﬁll data gaps within the group. At best, such
justiﬁcations should be founded on information regarding the
MoA driving the endpoint under consideration (Oomen et al.,
2014a,b).
Similar to the grouping considerations put forward by the
German competent authorities or the US NIOSH, one purpose for
NM grouping addressed in the EU projects is to rank NMs, i.e. pri-
oritize for testing. During ranking, NMs are ‘assigned a position in a
scale’, e.g. based on their potential for exposure (e.g. high dusti-
ness) and/or high intrinsic toxicity. As such, ranking of different
types of NMs does not necessarily imply a relationship between
the NMs. NM grouping, by contrast, implies that the combined
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ingly, ranking can be performed within groups of NMs, but also
entire groups can be ranked (Zuin et al., 2011).
The European Nanotechnology Industries Association (NIA,
2013) suggests a broad spectrum of criteria that might be used
for the grouping of NMs, i.e. high aspect ratio NMs, rigidity, metal
oxides, ion generation, ROS generation (reactive oxygen species),
crystalline structure, organic/inorganic, softness/hardness, lipid/
non-lipid, quantum effects, natural complex substances, inhalation
studies. This mixture of parameters encompasses the spectrum of
criteria suggested by Oomen et al. (2014a,b).
NIA (2013) provide a practical example for the grouping of NMs
in accordance with the ‘ion release hypothesis’: This hypothesis is
based upon the assumption that, e.g., Ag NMs are of equivalent or
lower toxicity than the corresponding silver ions – and that this is
true irrespective of particle size or coating type. Accordingly, read-
across from ionic Ag or nanoform Ag to non-nano Ag would be
valid and conservative.
Oomen et al. (2014a,b) underline that NM grouping strategies
are closely linked to NM testing strategies, i.e. integrated
approaches for testing and assessment (IATAs). Both aim at deter-
mining the identical concerns and apply the same criteria to do so.
In IATAs, ‘NMs of concern’ are identiﬁed based on relevant expo-
sure scenarios and the physico-chemical characteristics of the spe-
ciﬁc NM during its life cycle. IATAs proceed through a number of
tiers where, ﬁrst, all existing, and subsequently, if necessary, newly
gained, information on exposure, kinetics and hazard of the NM is
considered taking into account its entire life cycle. At the end of
each tier, all information gathered at that stage is evaluated to
derive a more comprehensive conclusion. Step-by-step, concerns
are reﬁned, and the uncertainty about potential risks is reduced.
This stepwise identiﬁcation and reﬁnement of concerns during
hazard assessment automatically implies some form of grouping
(Oomen et al., 2014a,b; van Tongeren et al., 2013; Stone et al.,
2013, 2014).
The key elements of IATAs and concern evaluation are ﬂexibility
and efﬁciency. Flexibility implies the incentive to deﬁne the most
appropriate information requirements that best address the
respective concern. The key element efﬁciency refers to the goal
to only collect those pieces of information that are really needed
(van Tongeren et al., 2013). IATAs can stop at any given tier as soon
as sufﬁcient certainty on the conclusion to be drawn is obtained. If
further information is considered necessary at the end of a given
tier, speciﬁc tests targeted to the relevant concerns can be selected
based on the information of the previous tiers applying increas-
ingly speciﬁc tools from tier to tier to collect or generate informa-
tion. While advancing to higher tiers, the total amount of data and
their complexity increases, uncertainty is progressively reduced,
and the assessment becomes more and more realistic and detailed
(Oomen et al., 2014a,b).
An important challenge in developing concepts on the grouping
of NMs is to enable simultaneously identifying and assessing the
impact of different physico-chemical properties on the harm the
NMs may induce. The NanoMILE project (Lynch et al., 2014) sug-
gests a grouping strategy that interlinks key physico-chemical
descriptors to predict nanoparticle toxicity as the sum of three
quantiﬁable parameters capturing the diversity of MoAs, i.e. their
intrinsic (inherent) properties (e.g. shape, porosity, structural con-
ﬁguration and band gap); chemical composition (inherent molecular
toxicity, charge, hydrophobicity and coating); and extrinsic proper-
ties (alterations in binding of biomolecules – interaction with
media, formation of molecular coronas – and resultant biomolecule
conformational effects (e.g. unfolding, receptor activation, mem-
brane damage, ﬁbrillation etc.).
The NanoMILE approach is founded on previous work by Sayes
et al. (2013) demonstrating the feasibility of grouping of NMsbased on combinations of related physico-chemical properties.
Using principal component analysis (PCA) and linear discriminant
analysis, Sayes et al. assessed which properties of a set of selected
physico-chemical properties (engineered size, concentration,
agglomerated size in water, zeta potential, pH and age of the sus-
pension, and oxidant production) were redundant in terms of their
detectable linear interdependencies across different silver, copper,
nickel, zinc and iron NMs. Sayes et al. further assessed which fea-
tures were best suited to discriminate between NM groups that
were based on known similarities (e.g. potential for dissolution)
or measured values (e.g. zeta potential, agglomeration in solution).
As an outcome of these assessments, the seemingly homogeneous
group of metal NMs could be further sub-grouped.
Similarly, Simko et al. (2014) address the following crucial
material properties determining the ‘effective dosages’ reaching
cells upon in vitro or in vivo test substance application: speciﬁc sur-
face area, surface textures, surface charge (inﬂuencing particle
absorption, corona formation and biokinetics), particle morphol-
ogy (e.g. different shapes and aspect ratios of ﬁbers vs. glomerular
particles), band gap energy levels of metal and metal oxide NMs
(affecting catalytic activity and ROS formation), and particle disso-
lution rate (affecting ion release). Also the FP7-funded NanoSolu-
tions project is aiming at identifying and elaborating those
characteristics of NMs that determine their biological hazard
potential with the goal to develop a computer program that allows
predicting NM human health hazards based upon NM properties.6. Research activities putting NM grouping into practice
A vast number of research papers are available addressing NM
toxicity in vitro or in vivo. Due to scientiﬁc shortages, e.g. in the
study design, the physico-chemical characterization of the test
substances, or the selection of appropriate dosages in vitro that
reﬂect realistic exposure scenarios in vivo, many studies are of lim-
ited value in adding knowledge on the toxic potential of NMs
(Landsiedel et al., 2014). However, a few publications describe
comprehensive ‘multiple perspective’ approaches for NM toxicity
testing that address NM complexity by making use of high-
throughput screening platforms and computational tools for data
evaluation. In the following, the work from A. Nel and co-workers
(e.g., Nel et al., 2013), Lai (2012), Shaw et al. (2008), and Cho et al.
(2013) in presented in further detail to show how NM grouping can
be put into practice for NM hazard assessment (Table 3). NM
grouping is not only applied to substantiate the interpretation of
test results and to rank NMs, but also to support the selection of
test methods and justify transitions from in vitro to in vivo testing.
All of the evaluated approaches conﬁrm the need to interlink
different relevant material properties of NMs for NM hazard
assessment. Furthermore, they provide initial indications how
concern-driven IATAs that are founded on NM grouping might be
applied for regulatory NM hazard assessment.6.1. Predictive toxicological approach (e.g. Nel et al., 2013)
The University of California Center for the Environmental Impli-
cations of Nanotechnology (UC CEIN; USA), led by A.E. Nel, has
developed a predictive toxicological approach using mechanism-
based in vitro assays for high-throughput screening (HTS) of
NMs. The HTS platform simultaneously measures a set of sub-
lethal and lethal cellular endpoints reﬂecting important toxicity
pathways for NMs, such as inﬂammatory reactions induced by Ag
and ZnO NMs that shed toxic ions, surface reactivity-induced redox
activity and ROS production for, e.g. TiO2 NMs, membrane lysis
elicited by partly soluble SiO2 NMs, or ﬁber-like toxicity caused
by high aspect ratio NMs, such as carbon nanotubes (Fig. 3). In
Fig. 3. Mechanistic injury pathways recognized for NMs (from: Nel et al., 2013; reprinted with the permission of the author).
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alveolar macrophage RAW264.7 cells are submitted to cellular
staining with ﬂuorescent probes and high content epi-ﬂuorescence
microscopy, ATP, lactate dehydrogenase (LDH), and tetrazolium
salt assays, and inductively-coupled plasma-mass spectrometry
analysis (detecting heavy metal ion release). Additionally, the UC
CEIN HTS platform includes physico-chemical characterization
studies and studies with zebra ﬁsh embryos (Meng et al., 2009;
Damoiseaux et al., 2011; George et al., 2011; Thomas et al., 2011
Xia et al., 2012; Zhang et al., 2012; Nel et al., 2013).
Of note, already in 1999, Rehn et al. from the University of
Essen, Germany, described a multi-parametric in vitro testing bat-
tery using isolated alveolar macrophages for the screening of pul-
monary effects of dust aerosols. By combining the results obtained
for a set of independent endpoints (esterase activation, release of
H2O2, glucuronidase and LDH, induction of tumor necrosis factor
alpha, and ROS generation), assay sensitivity and speciﬁcity could
be improved in comparison to single endpoint cytotoxicity assays,
and distinct toxicity patterns of different dusts could be discerned
(Rehn et al., 1999). These mentioned endpoints cover the four basic
principles of (nano)dust toxicity, i.e. ROS generation, release of
inﬂammatory mediators, impairment of cellular function, cytotox-
icity (Schnekenburger et al., 2009), and reﬂect the toxicity path-
ways covered in the HTS platform of the UC CEIN.
In the predictive toxicological approach described by Nel et al.,
the in vitro screening assays are evaluated to quantitatively assess
dose- and time-dependent molecular initiating events and toxicity
pathways that are predictive of in vivo adverse outcomes (which
would then have to be conﬁrmed in limited rodent studies). Data
from the HTS platforms are provided in a multivariate context
(e.g. concentration, exposure times, sub-lethal and lethal biological
responses). Due to the complexity of the data, feature-extraction
methods are applied for visual data interpretation. So-called
‘heat-map clusters’ provide ordered representations of data
allowing to identify similarity patterns of large datasets based on
homologous biological responses or linkage to physico-chemical
properties. Data obtained with the HTS assays are evaluated to
make predictions about those physico-chemical properties of
NMs that may lead to the generation of adverse effects in vivo.
Thereby, multi-parametric mechanism-based HTS approachescombined with heat-map clustering enable the development
of nanostructure–activity relationships and NM grouping
(Damoiseaux et al., 2011; George et al., 2011; Liu et al., 2011;
Rallo et al., 2011; Thomas et al., 2011; Nel et al., 2013).
6.2. High-throughput screening NM toxicity testing paradigm (Lai,
2012)
In 2012, D.Y. Lai from the US EPA presented a paradigm for NM
toxicity testing that also puts emphasis on in vitro assays combined
in a high-throughput screening platform. The testing paradigm fur-
ther suggests selecting reference materials for different classes of
NMs having unique physico-chemical characteristics, which may
lead to different biological effects by different mechanisms of
action. Accordingly, the NM testing paradigm consists of the fol-
lowing steps (Lai, 2012):
1. Assessment of toxicological effects of well-characterized
reference NMs by short-term in vivo studies; investigation of
molecular mechanisms underlying the effects; identiﬁcation
of key toxicity pathways by in vivo and in vitro high-throughput
genomics or proteomics assays. In parallel, conduction of short-
term in vivo studies to aid in interpretation of the responses and
provide data for physiologically-based pharmacokinetics model
development.
2. Testing of the reference materials by mechanism-based short-
term in vitro assays using human cells or cell lines of target tis-
sues to support interpretation of toxicity pathways. Again, the
spectrum of selected assays, i.e. DCF-DA assays for oxidative
stress/ROS, ELISA assay for cytokines, comet assays for DNA
damage, TUNEL assays for apoptosis, etc., reﬂect important tox-
icity pathways recognized for NMs.
3. Evaluation of potential hazard of selected NMs of varying
physico-chemical characteristics within class/subclass by con-
ducting high-throughput in vitro assays and mechanism-based
short-term in vivo assays and comparing data with those of
reference materials of speciﬁc class/subclass.
4. Identiﬁcation of physico-chemical parameter(s) and cut-off
values of parameter(s) that contribute to toxicity of each NM
class/subclass.
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text of the EPA’s ToxCast™ HTS program. Wang et al. (2013a)
tested 62 different NMs (mainly metal and metal oxide NMs and
their ion and micron-scale counterparts and carbon nanotubes),
taking into account potential exposure levels to determine test
concentrations and using computational tools for organizing and
analyzing data. Soluble NMs and their corresponding ions were
found to have similar proﬁles, whereas different carbon nanotubes
elicited different inﬂammatory proﬁles at non-cytotoxic concen-
trations. Overall, the core chemical composition of the given NM
seemed to exert a greater inﬂuence on its biological effects than
its size, but micron-scale materials were generally ranked lower
than the corresponding NMs. Application of the HTS platform
allowed prioritizing NMs for targeted testing, identifying affected
biological pathways, and linking NM properties in vitro to potential
in vivo effects (Wang et al., 2013b).
The need for a thorough assessment of the physico-chemical
characteristics of NM is seen as a major obstacle in implementing
HTS platforms. Particle characterization is time consuming and,
additionally, might require larger amounts of test material than
the test methods themselves (Wang et al., 2013a). To reduce the
efforts for NM characterization, a ‘minimal characterization’
scheme is suggested including size distribution of primary parti-
cles and agglomerates, chemical composition (including surface
and core, purity, and any impurities), surface area and reactivity,
solubility/dissolution and stability. Additional characteristics
might need to be assessed for speciﬁc types of NMs, e.g. crystallin-
ity for TiO2 NMs or dissolution properties for ion-shedding NMs,
and particle characterization should further take into account that
NM properties can change over time (Wang et al., 2013a).6.3. Perturbational proﬁling of NM biological activity (Shaw et al.,
2008)
Shaw et al. (2008) from Harvard University, USA, developed a
systematic approach to comprehensively investigate in vitro NM
effects by a so-called perturbational proﬁling of NM biological activ-
ity, i.e. a proﬁling of biological dysfunctions (perturbances). The set
of in vitro assays covers different cell types (endothelial cells,
smooth muscle cells, monocytes, hepatocytes) and includes the
ATP assay, C12-resazurin assessment of reducing equivalents, cas-
pase activation, and JC1 measurement of mitochondrial membrane
potential. For each NM, multiple doses over a 30-fold concentra-
tion range are submitted to all possible assay combinations. Test
results are expressed by a proﬁle that jointly addresses applied
dosage, cell type, and determined endpoint. These proﬁles are sub-
mitted to ‘unsupervised hierarchical clustering’ and ‘consensus
clustering’ to identify NMs with similar patterns of biologic activ-
ity. ‘Consensus clustering’ implies iteratively repeating the hierar-
chical clustering algorithm with different data sub-samples
thereby increasing the robustness of the clustering. The output of
‘consensus clustering’ is the fraction of clustering runs in which
any two NMs cluster together. The greater the co-clustering fre-
quency, the more likely it is that recognized clusters truly reﬂect
an underlying structure (Shaw et al., 2008).
Shaw et al. applied the perturbational proﬁling approach to
evaluate 50 different metal and metal oxide NMs possessing vary-
ing core compositions, coatings, and surface attachments. Overall,
the NMs showed very divergent activity proﬁles. The clustering
analyses yielded detailed structure–activity relationships and
divided the set of NMs into three main clusters. Shaw et al. con-
cluded that the biologic activity of NMs arises from the combined
effects of many aspects of the NM composition. For the NMs tested,
the core composition appeared to exert a strong (and unantici-
pated) inﬂuence on biologic activity. A subset of the 50 NMs wastested in mice, and NMs with similar activity proﬁles in vitro
exerted similar effects on in vivo monocyte numbers in the blood
and spleen (Shaw et al., 2008).6.4. Mechanism-based predictive testing approach (Cho et al., 2013)
Cho et al. (2013) from the University of Edinburgh, United King-
dom, suggest a mechanism-based predictive approach for the test-
ing of ion shedding NMs and those acting via surface reactivity. The
in vitro test systems cover 8 different cell-based assays including
epithelial cells (A549 and 16HBE-cells), monocytic/macrophage
cells (THP-1 cells, peripheral blood mononuclear cells), human
erythrocytes, and combined cultures (subsequent treatment of ﬁrst
THP-1 and then A549 cells). In vitro toxicity endpoints comprise
cytotoxicity (LDH release and trypan blue exclusion with or with-
out addition of cytochalasin D to evaluate the role of phagocytosis),
cytokine induction (interleukin-1beta, interleukin-8 and tumor
necrosis factor-alpha), and hemolytic potential (determination of
released hemoglobin). In putting the approach in practice, nine dif-
ferent NMs (CeO2, TiO2, carbon black, SiO2, NiO, Co3O4, Cr2O3, CuO,
and ZnO) were submitted to all combinations of the in vitro assays,
and test results were compared with in vivo acute lung inﬂammog-
enicity in a rat instillation model at same surface area dosages
(30 cm2/mL) of the test substances (Cho et al., 2013).
Acting via soluble toxic ions, NMs, such as ZnO or CuO, showed
positive results in most in vitro assays, and the results were consis-
tent with the lung inﬂammation data. Of the poorly soluble NMs
acting via surface reactivity, only CeO2 NMs elicited some degree
of in vitro effects. Cytotoxicity in differentiated peripheral blood
mononuclear cells was the most accurate in vitro parameter in pre-
dicting acute lung inﬂammogenicity (89% accuracy and 11% false
negativity). The outcome of the hemolysis assay was 100% consis-
tent with lung inﬂammation provided that any dose having statis-
tical signiﬁcance was assessed as ‘positive’ (Cho et al., 2013).7. Summary and conclusion
To provide a basis for speciﬁc regulatory provisions for NM
safety assessment, different countries and jurisdictions have laid
down deﬁnitions of the term ‘nanomaterial’. While the precise
components of these deﬁnitions vary, all of them are based on
material characteristics. However, the underlying nanomaterial
properties are neither mono-causal, nor linearly related to the
hazard or risk of NMs. Basing NM hazard and risk assessment on
such material properties is likely to result in the over- or under-
estimation of hazards or failure to recognize relevant risks at all.
The grouping of substances is widely recognized as an impor-
tant means to streamline toxicological testing for regulatory pur-
poses. General grouping approaches for chemicals (not explicitly
covering NMs) have already been implemented in, e.g., the EU
REACH regulation. By contrast, to date there are no regulatory doc-
uments providing speciﬁc frameworks for the grouping of NMs in
any of the jurisdictions evaluated in the present survey (i.e. EU,
USA, Canada, Japan, or Australia). Nevertheless, the grouping of
NMs is being addressed in publications from regulatory authorities
or international research consortia, and preliminary guidance has
been published in the context of substance-related legislation or
in the occupational setting.
In their broad conceptual design, the evaluated approaches for
the grouping of NMs are consistent or complement each other.
Overall, the NM categories proposed in these concepts cover the
range of aspects of NMs that have been recognized as relevant
for NM hazard and risk assessment. For instance, material proper-
ties and biophysical interactions are addressed in the categoriza-
tion scheme of the German Federal Institute for Occupational
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component of the grouping concepts of the US National Institute
for Occupational Safety and Health (Kuempel et al., 2012; DHHS
(NIOSH), 2012). NM uptake is an integral part of the NanoDiv™
testing scheme (Anzai et al., 2012) or is addressed in the testing
approach published by Monteiro-Riviere et al. (2011). Deﬁned
mechanisms of NM toxicity form the basis of the grouping and
testing approaches published by Nel et al. (2013), Lai (2012),
Shaw et al. (2008), or Cho et al. (2013). Furthermore, most NM cat-
egorizations are founded on quantiﬁable parameters (e.g. material
properties and biophysical interactions) or the toxicological effects
of the corresponding chemicals or larger particles of the same
chemical composition (which can be assessed in accepted test
methods).
In summary, all of the available proposals for the grouping of
NMs already go beyond the determination of mere (quantitative)
structure–activity relationships. They are founded on different
aspects of the NM life cycle, even though none of the proposals
fully takes into account all relevant parameters. Most of the
grouping approaches cover different material properties, some
the toxicological effects of the corresponding bulk materials or, less
frequently, toxicological MoAs of the NMs. NM exposure and use
scenarios are only occasionally addressed. Nevertheless, by found-
ing NM grouping on different combinations of relevant aspects of a
NM’s life cycle, the spectrum of available concepts for the grouping
of NMs forms a sound scientiﬁc basis to advance regulatory provi-
sions on the grouping of NMs. Future research should aim at com-
bining the available concepts into a comprehensive ‘multiple
perspective’ framework for the grouping of NMs.
This comprehensive, ‘multiple perspective’ framework should
take into account the pathway from the release of the NM to the
apical toxic effect. The concept should address the different stages
of the NM’s life cycle, since risks can change, e.g. once a nanoform
powder is embedded in a composite. The ‘multiple perspective’
framework should consider NM material properties and biophysi-
cal interactions, their use and exposure, their uptake and kinetics,
just as possible early and apical biological effects. In this respect,
however, a ‘multiple perspective’ approach does not imply ﬁxed
testing schemes for all NMs in all applications. On the contrary,
such ‘tick-box’ testing would result in the collection of vast
amounts of scientiﬁcally unnecessary information, which is neither
desirable on animal welfare grounds, nor for economic reasons.
Instead, a comprehensive ‘multiple perspective’ grouping approach
that is closely linked to IATAs by supporting a concern-driven step-
wise collection and evaluation of information that is truly relevant
for the given purpose is recommended for use. In the second part of
its assignment, the ECETOC TF on grouping and IATAs of nanoma-
terials will put forward a proposal for such a comprehensive ‘mul-
tiple perspective’ grouping approach.
To ensure its practicality, the ‘multiple perspective’ NM group-
ing framework should indicate speciﬁc test methods that allow
generating the necessary data to assign NMs to the different groups
and that is required for a concern-driven ranking of NMs within a
group or between different groups of NMs. In this respect, high
throughput screening platforms and the computational evaluation
of data appear important tools to address NM complexity during
grouping or hazard assessment. A further challenge lies in deﬁning
criteria to justify the assignment of a NM to a group of similar con-
cern. For this purpose, case studies should be initiated to verify the
quality and robustness of the grouping framework, since most of
the currently available approaches have not yet advanced beyond
theoretical, conceptual stages.
Overall, a comprehensive, ‘multiple perspective’ NM grouping
framework, linked to concern-driven IATAs, serves to streamline
testing to the collection of data that is relevant for NM safety
assessment. Since the ‘multiple perspective’ framework is foundedon scientiﬁcally justiﬁable categories, safe uses of NMs can be
identiﬁed and unsafe uses excluded. Finally, the ‘multiple perspec-
tive’ NM grouping framework allows assessing NMs economically
and in a timesaving manner and contributes to replacing, reducing,
and reﬁning the need for animal testing (Russell and Burch, 1959).
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